In an uncertain market environment, investors should look for stocks that can win over the long run based on their strong fundamentals and solid growth prospects. We think Walmart (WMT), Tencent (TNC), ComVault Systems (CVLT), and Vertex Pharmaceuticals (VRTX) could be good choices on that front. For more information, read….
The stock market has suffered significant pain since the beginning of the year due to various macroeconomic and geopolitical constraints. Wall Street expects a recession later this year due to the Fed’s aggressive interest rate hikes, which could put further pressure on the stock market.
However, long-term investors should not be bothered by short-term market volatility. Instead of trying to navigate short-term turmoil, they should buy declining stocks that have the potential to deliver solid returns based on their strong revenue and earnings growth.
We think, quality stock Walmart Inc. ,wmt), tenant company (TNC), Comvault Systems, Inc. ,CVLT), and Vertex Pharmaceuticals Incorporated (VRTX) can yield substantial gains in the long run. Therefore, it may be wise to add them to your portfolio now.
Walmart Inc. ,wmt,
Well-known retailer WMT operates supercenters, supermarkets, hypermarkets, warehouse clubs, cash and carry stores, discount stores, membership-only warehouse clubs and e-commerce websites, including walmart.com and Walmart.com.mx flipkart.com, and Others are included. The company operates through the Walmart US, Walmart International and Sam’s Club segments.
On June 29, 2022, WMT announced that it has agreed to acquire Memomi, reinforcing WMT’s commitment to frictionless and omnichannel optical care. “This acquisition supports our health and wellness mission to provide accessible care to the communities we serve,” said David Reitnauer, WMT’s VP of Health and Wellness, Specialty Services.
WMT revenue grew 2.4% year-over-year to $141.56 billion for the first quarter ended April 30, 2022. of the company current assets It grew 8.6% year-over-year to $83.22 billion. In addition, its long-term debt declined 20.1% year-on-year to $32.17 billion.
Analysts expect WMT’s EPS to rise 8.4% year-on-year to $6.97 for fiscal 2024. Its revenue is expected to grow 4.2% year-over-year to $596.97 billion for fiscal year 2023. It outperformed Street EPS estimates in three of the last four quarters. Over the past month, the stock has fallen 1.7% to close the previous trading session at $121.98.
wmt power rating Shows solid possibilities. According to our proprietary rating system, it has an overall rating of B, which translates into a buy. PoWR Ratings assesses stocks based on 118 different factors, each with its own weighting.
It has a B grade for stability. It’s A-rated. Ranked #23 out of 38 stocks in Grocery/Big Box Retailer industry. click here To view WMT’s other ratings for Growth, Value, Momentum, Sentiment and Quality.
tenant company (TNC,
TNC designs, manufactures and markets floor cleaning equipment. It offers its products under the brands Tennant, Nobles, Alfa Uma Empresa Tennant, IRIS, VLX, IPC, Gaomei, Ronge, and Rongen.
On April 5, 2022, TNC introduced lithium-ion technology to its portfolio of AMR machines, including the T380AMR, T7AMR, and T16AMR. Barb Balinsky, TNC’s Senior VP, Innovation and Technology, said, “With long-lasting and hassle-free maintenance, lithium-ion powered robotic scrubbers help our customers increase their cleaning efficiency and optimize employee resources even more. will do.”
For the fiscal first quarter ended March 31, 2022, TNC’s net sales decreased 2% year-over-year to $258.10 million. The company’s adjusted EBITDA decreased 31.4% year-over-year to $27.90 million. Also, its current liabilities declined 8.2% to $266.40 million, as compared to $290.30 million for the fiscal year ended December 31, 2021.
For fiscal year 2023, TNC’s EPS is expected to increase 10.5% year-on-year to $4.73. Its revenue is expected to grow 11.3% year-over-year to $302.80 million for the quarter ended September 30, 2022. It exceeded consensus EPS estimates in three of the last four quarters. Over the past month, the stock is up 5.9% to close the previous trading session at $63.05.
TNC’s POWR rating reflects this promising outlook. The stock has an overall rating of A, which equates to a strong buy in our proprietary rating system.
It has a B grade for price, consistency and quality. It’s B-rated. Ranked #2 out of 80 stocks in industrial equipment industry. To see TNC’s other ratings for Growth, Momentum and Sentiment, visit click here,
Comvault Systems, Inc. ,CVLT,
CVLT is a leader in providing data readiness, enabling its customers to manage data intelligently with solutions that store, protect, optimize and use data. Its software automates tasks and harnesses data, helping customers make informed business decisions. In addition, its solutions work in cloud, SaaS and on-premises environments.
CVLT’s total revenue increased 7.9% year-over-year to $197.98 million for the first quarter ended June 30, 2022. The company’s services segment revenue increased 4.2% year-over-year to $105.54 million. In addition, its non-GAAP EPS came in at $0.64, representing year-over-year growth of 3.2%.
Analysts expect CVLT’s EPS and revenue for fiscal 2024 to grow 22.4% and 7.3% year-over-year to $3.16 and $871.53 million, respectively. It outperformed Street EPS estimates in three of the last four quarters. Over the past nine months, the stock has lost 9.5% to close the previous trading session at $55.23.
CVLT’s strong fundamentals are reflected in its POWR rating. It has an overall rating of A, which equates to a strong buy in our proprietary rating system.
It has an A grade for quality and a B for growth and value. It is ranked #4 out of 154 stocks software application industry. click here To view CVLT’s other ratings for speed, stability and sentiment.
Vertex Pharmaceuticals Incorporated (VRTX,
VRTX is a biotechnology company focusing on the development and commercialization of therapies to treat cystic fibrosis (CF) and is advancing its research and development programs in other indications. The company’s marketed drugs include TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO.
On January 11, 2022, VRTX announced that the European Commission has approved a label expansion of KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of patients with cystic fibrosis in the 6-11 age group, Those who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.
For the fiscal first quarter ended March 31, 2022, VRTX’s non-GAAP operating income increased 16.4% year-over-year to $1.16 billion. The company’s non-GAAP net income increased 16.1% year-over-year to $907 million. In addition, its non-GAAP EPS came in at $3.52, representing an increase of 18.1% year-over-year.
For the quarter ended June 30, 2022, VRTX’s EPS is expected to grow 13.2% year-over-year to $3.52. Its revenue is expected to grow 16.3% year-over-year to $2.16 billion for the quarter ended September 30, 2022. It exceeded Street EPS estimates in each of the last four quarters. Over the past nine months, the stock is up 56.5% to close the previous trading session at $288.22.
The VRTX’s power rating shows solid prospects. The company has an overall rating of A, which translates into a strong buy in our proprietary rating system.
Shares of WMT rose $0.42 (+0.34%) in premarket trading on Wednesday. Year-on-year, the WMT is down -14.71%, while the benchmark S&P 500 index has gained -16.35% during the same period.
About the Author: Dipanjan Banchur
Since he was in grade school, Dipanjan was interested in the stock market. This earned him a master’s degree in finance and accounting. Currently, as an investment analyst and financial journalist, Dipanjan has a keen interest in reading and analyzing emerging trends in the financial markets.